WP1130 was first reported to block the aberrant BCR-ABL tyrosine kinase expressed in chronic myelogenous leukemia (CML) cells by increasing K63-linked polyubiquitination to induce its translocation to the aggresome [17,18], which is a perinuclear inclusion body containing aggregates of misfolded, ubiquitinated proteins, and chaperones [19]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.